Aclaris Therapeutics Inc. (NASDAQ:ACRS) major shareholder Ra Capital Management, Llc sold 525,550 shares of Aclaris Therapeutics stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $24.19, for a total value of $12,713,054.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Aclaris Therapeutics Inc. (NASDAQ:ACRS) opened at 25.03 on Friday. Aclaris Therapeutics Inc. has a 1-year low of $10.99 and a 1-year high of $33.88. The stock has a 50 day moving average of $21.38 and a 200-day moving average of $19.76. The company’s market cap is $536.02 million.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.01. On average, equities research analysts predict that Aclaris Therapeutics Inc. will post ($2.61) earnings per share for the current year.
A number of research analysts have recently issued reports on ACRS shares. Jefferies Group lifted their target price on shares of Aclaris Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a research note on Monday. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 23rd. Finally, Guggenheim started coverage on shares of Aclaris Therapeutics in a research note on Friday, June 10th. They issued a “buy” rating and a $35.00 target price for the company. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Aclaris Therapeutics presently has a consensus rating of “Buy” and an average price target of $31.25.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vivo Capital LLC bought a new position in Aclaris Therapeutics during the first quarter valued at $79,427,000. FIL Ltd bought a new position in Aclaris Therapeutics during the second quarter valued at $13,801,000. Vanguard Group Inc. boosted its position in Aclaris Therapeutics by 147.6% in the second quarter. Vanguard Group Inc. now owns 419,184 shares of the company’s stock valued at $7,743,000 after buying an additional 249,888 shares in the last quarter. BlackRock Fund Advisors boosted its position in Aclaris Therapeutics by 59.7% in the second quarter. BlackRock Fund Advisors now owns 234,696 shares of the company’s stock valued at $4,335,000 after buying an additional 87,739 shares in the last quarter. Finally, Monashee Investment Management LLC bought a new position in Aclaris Therapeutics during the second quarter valued at $1,108,000. 71.39% of the stock is currently owned by hedge funds and other institutional investors.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.